Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 17 | 2024 | 868 | 4.380 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 685 | 3.130 |
Why?
|
| Percutaneous Coronary Intervention | 8 | 2024 | 171 | 2.400 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 869 | 2.260 |
Why?
|
| Stroke | 13 | 2025 | 1144 | 2.130 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 254 | 2.050 |
Why?
|
| Cardiovascular Diseases | 11 | 2025 | 831 | 2.030 |
Why?
|
| Pharmacovigilance | 3 | 2024 | 13 | 2.020 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 253 | 1.770 |
Why?
|
| Endovascular Procedures | 3 | 2025 | 581 | 1.730 |
Why?
|
| Atrial Fibrillation | 12 | 2024 | 805 | 1.710 |
Why?
|
| Heart Arrest | 4 | 2023 | 161 | 1.700 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2025 | 118 | 1.630 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2024 | 98 | 1.520 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 1.460 |
Why?
|
| Humans | 88 | 2025 | 60093 | 1.380 |
Why?
|
| Catheter Ablation | 4 | 2024 | 141 | 1.360 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 120 | 1.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2025 | 673 | 1.270 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 172 | 1.260 |
Why?
|
| Treatment Outcome | 22 | 2025 | 5264 | 1.160 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2023 | 218 | 1.150 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2024 | 50 | 1.140 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 172 | 1.070 |
Why?
|
| Hospitalization | 19 | 2025 | 1304 | 1.070 |
Why?
|
| Cardiovascular Agents | 3 | 2023 | 101 | 1.010 |
Why?
|
| United States | 26 | 2025 | 7608 | 0.990 |
Why?
|
| Hospital Mortality | 14 | 2025 | 856 | 0.980 |
Why?
|
| Risk Factors | 19 | 2025 | 5086 | 0.950 |
Why?
|
| Heart Transplantation | 3 | 2024 | 159 | 0.940 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.910 |
Why?
|
| Bayes Theorem | 1 | 2024 | 106 | 0.910 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 95 | 0.890 |
Why?
|
| Myocardial Revascularization | 1 | 2024 | 72 | 0.880 |
Why?
|
| Health Care Costs | 2 | 2022 | 210 | 0.860 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2023 | 14 | 0.850 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 276 | 0.840 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 17 | 0.830 |
Why?
|
| Neoplasms | 9 | 2025 | 1261 | 0.830 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 258 | 0.820 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2023 | 45 | 0.820 |
Why?
|
| Recovery of Function | 1 | 2024 | 267 | 0.810 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 52 | 0.810 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 54 | 0.810 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 88 | 0.800 |
Why?
|
| Aged | 24 | 2025 | 13581 | 0.790 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 85 | 0.790 |
Why?
|
| Thrombectomy | 1 | 2024 | 207 | 0.790 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 157 | 0.780 |
Why?
|
| Mortality, Premature | 1 | 2021 | 6 | 0.780 |
Why?
|
| Inpatients | 9 | 2024 | 300 | 0.770 |
Why?
|
| Heart-Assist Devices | 5 | 2025 | 129 | 0.770 |
Why?
|
| Stroke Volume | 5 | 2024 | 323 | 0.760 |
Why?
|
| Hyperkalemia | 1 | 2021 | 23 | 0.740 |
Why?
|
| Medicare | 2 | 2023 | 599 | 0.740 |
Why?
|
| Retrospective Studies | 17 | 2025 | 6136 | 0.740 |
Why?
|
| Male | 28 | 2025 | 27963 | 0.730 |
Why?
|
| Hypotension | 1 | 2021 | 47 | 0.730 |
Why?
|
| Female | 31 | 2025 | 31229 | 0.720 |
Why?
|
| Adult | 27 | 2025 | 15980 | 0.720 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 158 | 0.720 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 118 | 0.700 |
Why?
|
| Length of Stay | 9 | 2025 | 781 | 0.700 |
Why?
|
| Cardiovascular System | 1 | 2020 | 41 | 0.690 |
Why?
|
| Kidney Diseases | 1 | 2021 | 160 | 0.670 |
Why?
|
| Databases, Factual | 5 | 2025 | 849 | 0.630 |
Why?
|
| Dementia | 1 | 2022 | 252 | 0.630 |
Why?
|
| Secondary Prevention | 1 | 2019 | 154 | 0.620 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 754 | 0.580 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2024 | 77 | 0.580 |
Why?
|
| Young Adult | 10 | 2025 | 4394 | 0.560 |
Why?
|
| Atrial Appendage | 3 | 2022 | 28 | 0.560 |
Why?
|
| Middle Aged | 19 | 2025 | 16540 | 0.540 |
Why?
|
| Cardiotoxicity | 4 | 2025 | 16 | 0.540 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2024 | 157 | 0.520 |
Why?
|
| Brain Ischemia | 1 | 2019 | 402 | 0.490 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 5192 | 0.470 |
Why?
|
| Adolescent | 9 | 2025 | 5957 | 0.440 |
Why?
|
| Time Factors | 5 | 2024 | 3619 | 0.430 |
Why?
|
| Pandemics | 5 | 2023 | 629 | 0.400 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.400 |
Why?
|
| Myocarditis | 3 | 2024 | 61 | 0.400 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 13 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 76 | 0.390 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 91 | 0.370 |
Why?
|
| Hospitals | 6 | 2024 | 377 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 193 | 0.370 |
Why?
|
| Valsartan | 2 | 2021 | 11 | 0.370 |
Why?
|
| Aminobutyrates | 2 | 2021 | 10 | 0.370 |
Why?
|
| Tetrazoles | 2 | 2021 | 20 | 0.370 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 29 | 0.360 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 275 | 0.360 |
Why?
|
| Drug Combinations | 2 | 2021 | 138 | 0.360 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 63 | 0.350 |
Why?
|
| Aortic Valve | 4 | 2024 | 172 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 132 | 0.320 |
Why?
|
| Atherosclerosis | 2 | 2021 | 148 | 0.320 |
Why?
|
| Ritonavir | 3 | 2023 | 14 | 0.320 |
Why?
|
| Hypertension | 2 | 2024 | 601 | 0.310 |
Why?
|
| Hemorrhage | 3 | 2024 | 272 | 0.290 |
Why?
|
| Shock, Cardiogenic | 2 | 2025 | 88 | 0.270 |
Why?
|
| Obesity | 2 | 2024 | 1191 | 0.260 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 61 | 0.260 |
Why?
|
| Anticoagulants | 4 | 2022 | 488 | 0.260 |
Why?
|
| Child | 3 | 2024 | 4332 | 0.250 |
Why?
|
| Femoral Artery | 2 | 2023 | 94 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 209 | 0.250 |
Why?
|
| Mitral Valve | 2 | 2023 | 105 | 0.250 |
Why?
|
| Blood Pressure | 2 | 2025 | 522 | 0.250 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 264 | 0.240 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 537 | 0.240 |
Why?
|
| Water Pollutants, Chemical | 1 | 2025 | 40 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 18 | 0.230 |
Why?
|
| Canagliflozin | 1 | 2024 | 5 | 0.230 |
Why?
|
| Glucosides | 1 | 2024 | 13 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 34 | 0.230 |
Why?
|
| Perioperative Care | 1 | 2025 | 79 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 77 | 0.220 |
Why?
|
| Furosemide | 1 | 2023 | 17 | 0.220 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 48 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 105 | 0.220 |
Why?
|
| Ibuprofen | 1 | 2023 | 18 | 0.220 |
Why?
|
| Indomethacin | 1 | 2023 | 20 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2023 | 24 | 0.220 |
Why?
|
| Propensity Score | 1 | 2024 | 138 | 0.220 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 99 | 0.210 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 58 | 0.210 |
Why?
|
| Environmental Exposure | 1 | 2025 | 212 | 0.210 |
Why?
|
| Rural Population | 2 | 2022 | 193 | 0.210 |
Why?
|
| Prealbumin | 1 | 2023 | 20 | 0.210 |
Why?
|
| Catheterization, Peripheral | 1 | 2023 | 46 | 0.210 |
Why?
|
| Popliteal Artery | 1 | 2023 | 25 | 0.210 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 13 | 0.210 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 13 | 0.210 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 41 | 0.210 |
Why?
|
| Disability Evaluation | 1 | 2024 | 217 | 0.210 |
Why?
|
| Vascular Patency | 1 | 2023 | 132 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2023 | 91 | 0.200 |
Why?
|
| Climate Change | 1 | 2022 | 16 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 152 | 0.200 |
Why?
|
| Reoperation | 1 | 2023 | 269 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2025 | 235 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1312 | 0.200 |
Why?
|
| Overweight | 1 | 2024 | 249 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2023 | 198 | 0.190 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 31 | 0.190 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 143 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 109 | 0.190 |
Why?
|
| Algorithms | 2 | 2024 | 1000 | 0.190 |
Why?
|
| Infant, Premature | 1 | 2023 | 180 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 443 | 0.190 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2022 | 354 | 0.190 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2021 | 33 | 0.190 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 143 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 39 | 0.190 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 11 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 215 | 0.180 |
Why?
|
| Giant Cells | 1 | 2021 | 17 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2022 | 206 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 171 | 0.180 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 62 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 142 | 0.180 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Cardiology | 1 | 2022 | 163 | 0.170 |
Why?
|
| Anemia | 1 | 2021 | 119 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 67 | 0.170 |
Why?
|
| Cardiac Catheterization | 4 | 2022 | 254 | 0.170 |
Why?
|
| Asthma | 1 | 2023 | 423 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2023 | 424 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 424 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 164 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 646 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 570 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 191 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1175 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 203 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1132 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1139 | 0.120 |
Why?
|
| Comorbidity | 3 | 2023 | 1097 | 0.120 |
Why?
|
| Mortality | 2 | 2025 | 165 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2012 | 250 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2501 | 0.100 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 51 | 0.090 |
Why?
|
| Warfarin | 2 | 2022 | 110 | 0.090 |
Why?
|
| Prevalence | 2 | 2025 | 1295 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 46 | 0.090 |
Why?
|
| Coronary Angiography | 2 | 2023 | 177 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2477 | 0.070 |
Why?
|
| Pregnancy | 2 | 2024 | 2359 | 0.070 |
Why?
|
| Mobility Limitation | 1 | 2025 | 55 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 22 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 55 | 0.060 |
Why?
|
| Peripartum Period | 1 | 2024 | 31 | 0.060 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 86 | 0.050 |
Why?
|
| Spasm | 1 | 2023 | 9 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 11 | 0.050 |
Why?
|
| Diuretics | 1 | 2023 | 58 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 31 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 103 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 186 | 0.050 |
Why?
|
| Hematoma | 1 | 2023 | 74 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 93 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 109 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 12 | 0.050 |
Why?
|
| Radial Artery | 1 | 2023 | 49 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 123 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 113 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2022 | 71 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 48 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2022 | 57 | 0.050 |
Why?
|
| New Mexico | 1 | 2021 | 8 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 14 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 42 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 302 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 54 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2022 | 98 | 0.050 |
Why?
|
| Endocardium | 1 | 2021 | 12 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 165 | 0.050 |
Why?
|
| Troponin I | 1 | 2021 | 32 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 970 | 0.050 |
Why?
|
| California | 1 | 2021 | 162 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 52 | 0.050 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 255 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 262 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 166 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 317 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 309 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 558 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 397 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 460 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 376 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 186 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 304 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 930 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 276 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 428 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 529 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 892 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 546 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 1934 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1850 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1212 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1111 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3131 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2012 | 102 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 34 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 178 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1066 | 0.020 |
Why?
|